Navigation Links
Roche Diagnostics Named to FORTUNE magazine's 2013 list of "100 Best Companies to Work For"
Date:1/17/2013

, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Todd Siesky 
Director, Corporate Communications
Roche Diagnostics Corporation
Indianapolis, IN
(317) 521-3966
todd.siesky@roche.com


'/>"/>
SOURCE Roche Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter
3. Roche announces FDA approval of HIV viral load test
4. FDA clears Accu-Chek Combo system - Roches new interactive insulin pump system for people with diabetes
5. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
6. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
7. Rochester Medical Reports Third Quarter Results
8. Roche receives FDA clearance for herpes simplex virus type 1 and 2 tests
9. Roche Selects Thomson Reuters to Transform the Management of Its Intellectual Property Assets
10. Roche cytomegalovirus viral load test now available in US
11. Rochester Medical Announces Fourth Quarter 2012 Earnings Conference Call Tuesday, November 13, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 ... Das auf dem ESC-Kongress 2014 präsentierte ... Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten Patienten ... Die Daten der ... Patienten, einer innovativen und unabhängigen Forschungsinitiative ...
(Date:9/2/2014)... September 2, 2014 , ... 2014 provide insight into treatment and outcomes of ... practice --   Data from nearly ... in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent ... strategies for atrial fibrillation (AF) patients remain sub-optimal ...
(Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, the ... its investment in development and manufacturing capabilities with the ... Karl Mueller , Particle Sciences, Associate Director Clinical Production, ... adding clean room square footage, equipment and staff across ... The company now has over 6000ft 2 of ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
... , ... The Gamida Cell-Teva Joint Venture,(JV) announced today that the ... registration, Phase,III clinical trial of StemEx (called ExCell) and has recommended ... data analysis is,anticipated to take place during Q2 2010. StemEx is ...
... , Feb. 9 CareFusion Corp. (NYSE: ... from continuing operations for the three and six months ended ... during our second quarter and performed ahead of our expectations," said ... spending made modest improvements during the quarter and we continued to ...
Cached Medicine Technology:Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 2Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 3CareFusion Reports Second Quarter Results 2CareFusion Reports Second Quarter Results 3CareFusion Reports Second Quarter Results 4CareFusion Reports Second Quarter Results 5CareFusion Reports Second Quarter Results 6CareFusion Reports Second Quarter Results 7CareFusion Reports Second Quarter Results 8CareFusion Reports Second Quarter Results 9CareFusion Reports Second Quarter Results 10CareFusion Reports Second Quarter Results 11CareFusion Reports Second Quarter Results 12CareFusion Reports Second Quarter Results 13CareFusion Reports Second Quarter Results 14CareFusion Reports Second Quarter Results 15CareFusion Reports Second Quarter Results 16CareFusion Reports Second Quarter Results 17CareFusion Reports Second Quarter Results 18
(Date:9/2/2014)... (PRWEB) September 02, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical ... market is expected to grow to over ... by an increase in the number of procedures ... kidney stones. This market includes TURP devices, laser ...
(Date:9/2/2014)... September 02, 2014 Nanomedicine is ... in diagnosing, treating and/or prevention of diseases and ... treating cardiovascular, neurological, and oncology diseases. , ... pertaining to various nanoparticles, their medical usages, and ... exists considerable scope for research in this domain, ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present ... vida! Get Up! Get Moving!®. This event promotes Hispanic family ... for people of all ages and all sizes. The event, ... held at Kiest Park Recreation Center, 3080 S. Hampton Road, ... “Since 2007, we have partnered with National Alliance for Hispanic ...
(Date:9/2/2014)... 2014 Durable Medical Goods manufacture ... leasing and financing company LeaseQ, Inc. to help customers ... Since late 2012, LeaseQ’s breakthrough finance shopping platform has ... they need to run their business. , Said ... enable the ThermoTek sales team to provide customers faster ...
(Date:9/2/2014)... The American Healthcare Documentation Professionals Group (AHDPG) ... its ICD-10 Medical Coding Bridge Program. The purpose of ... confidence to students who are seeking to launch an ... with the uncertainty brought on by the federal government’s ... 1st, 2015. , AHDPG’s Free-Tuition Guarantee is simple and ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3
... public health researchers discuss whether or not the public ... (Swedish snus) is less hazardous to health than smoking ... information, Carol Gartner and Wayne Hall (University of Queensland, ... be widelyused as an alternative to cigarettes in Sweden, ...
... that girls as young as 15 are resorting to the drug ... ,The Amphetamine drugs that are snorted and injected contract appetite ... ,Robin Herne with Suffolk's Drug and Alcohol Action Team, said ... ,Herne warned that the drug can lead to binge eating, ...
... save your heart, for a new study has found ... ,Dr Alyson Mitchell and his team at ... using standardised farming techniques for the ten-year study. ... double the amount of flavonoids than compared to the ...
... risk of childhood asthma by as much as 70 ... five countries . ,The culprit gene, called ... online on Wednesday by the British science journal Nature, ... the United States and Austria joined the DNA trawl, ...
... million dollar space programme, will carry out scientific research ... in outer space, reports said Wednesday. ... the crystallisation of protein, said Abdul Rahman Abdul Jamal, ... University of Malaysia. ,"The research is aimed ...
... in St. Louis, Missouri, have found two antidotes which, ... deadliest poisons like Ricin, cholera toxin, and shiga toxin. ... E. coli bacteria, these toxins travel backwards through a ... endoplasmic reticulum before interrupting protein synthesis. ...
Cached Medicine News:Health News:Major Gene Link Seen to Childhood Asthma 2
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... perfecting mini-invasive endoscopic methods for ensuring extremely ... considerable social impact. The use of these ... and represents a valid backup in cutting ... family of Nd:YAG lasers is growing, developing ...
... hair removal for all skin ... Used for leg and facial ... Offers a large spot sizes ... fast treatment. An optional ...
Medicine Products: